Soligenix, Inc. Logo

Soligenix, Inc.

SNGX

(1.0)
Stock Price

4,01 USD

-81.65% ROA

-268.25% ROE

-0.96x PER

Market Cap.

8.823.546,00 USD

75.3% DER

0% Yield

-731.6% NPM

Soligenix, Inc. Stock Analysis

Soligenix, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Soligenix, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.5x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock maintains a fair debt to equity ratio (54%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-4558.46%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-80.31%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Soligenix, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Soligenix, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Soligenix, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Soligenix, Inc. Revenue
Year Revenue Growth
1995 0
1997 100.000 100%
1998 200.000 50%
1999 1 -19999900%
2000 0 0%
2001 0 0%
2002 0 0%
2003 83.817 100%
2004 997.482 91.6%
2005 3.075.736 67.57%
2006 2.313.020 -32.97%
2007 1.258.017 -83.86%
2008 2.310.265 45.55%
2009 2.816.037 17.96%
2010 1.947.628 -44.59%
2011 7.662.822 74.58%
2012 3.144.620 -143.68%
2013 3.224.152 2.47%
2014 7.043.016 54.22%
2015 8.768.390 19.68%
2016 10.448.794 16.08%
2017 5.432.472 -92.34%
2018 5.241.448 -3.64%
2019 4.629.916 -13.21%
2020 2.359.447 -96.23%
2021 824.268 -186.25%
2022 948.911 13.14%
2023 521.760 -81.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Soligenix, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1995 906.461
1997 1.800.000 49.64%
1998 3.100.000 41.94%
1999 2.028.945 -52.79%
2000 956.742 -112.07%
2001 2.470.801 61.28%
2002 2.943.493 16.06%
2003 2.729.430 -7.84%
2004 3.656.776 25.36%
2005 3.681.137 0.66%
2006 4.620.312 20.33%
2007 3.099.944 -49.05%
2008 1.734.491 -78.72%
2009 4.523.375 61.65%
2010 5.684.309 20.42%
2011 6.272.616 9.38%
2012 2.609.241 -140.4%
2013 5.071.179 48.55%
2014 5.086.535 0.3%
2015 5.399.839 5.8%
2016 4.295.867 -25.7%
2017 5.507.033 21.99%
2018 6.750.954 18.43%
2019 8.122.610 16.89%
2020 15.145.778 46.37%
2021 8.389.387 -80.53%
2022 7.944.089 -5.61%
2023 3.304.060 -140.43%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Soligenix, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 1.973.455 100%
2002 1.973.455 0%
2003 2.505.071 21.22%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 2.145.167 100%
2009 2.860.317 25%
2010 2.503.338 -14.26%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 3.209.155 100%
2018 2.951.760 -8.72%
2019 3.480.912 15.2%
2020 3.979.227 12.52%
2021 4.847.126 17.91%
2022 6.692.904 27.58%
2023 3.892.160 -71.96%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Soligenix, Inc. EBITDA
Year EBITDA Growth
1995 -1.058.376
1997 -2.900.000 63.5%
1998 10.500.000 127.62%
1999 -805.760 1403.12%
2000 -469.285 -71.7%
2001 -3.861.619 87.85%
2002 -6.454.877 40.18%
2003 -4.974.352 -29.76%
2004 -5.615.192 11.41%
2005 -4.640.767 -21%
2006 -7.246.204 35.96%
2007 -6.206.131 -16.76%
2008 -3.306.641 -87.69%
2009 -5.873.293 43.7%
2010 -7.680.651 23.53%
2011 -2.726.724 -181.68%
2012 -4.460.038 38.86%
2013 -3.271.701 -36.32%
2014 -5.951.757 45.03%
2015 -5.660.948 -5.14%
2016 -7.551.494 25.04%
2017 -7.525.236 -0.35%
2018 -9.014.921 16.52%
2019 -10.045.168 10.26%
2020 -18.428.776 45.49%
2021 -12.901.200 -42.85%
2022 -14.075.552 8.34%
2023 -7.272.000 -93.56%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Soligenix, Inc. Gross Profit
Year Gross Profit Growth
1995 0
1997 600.000 100%
1998 1.900.000 68.42%
1999 1.407.751 -34.97%
2000 0 0%
2001 0 0%
2002 0 0%
2003 7.620 100%
2004 60.846 87.48%
2005 1.008.702 93.97%
2006 347.946 -189.9%
2007 314.632 -10.59%
2008 423.834 25.77%
2009 1.332.396 68.19%
2010 309.226 -330.88%
2011 5.554.594 94.43%
2012 551.545 -907.1%
2013 679.867 18.87%
2014 1.729.161 60.68%
2015 1.886.186 8.33%
2016 2.015.123 6.4%
2017 1.122.389 -79.54%
2018 643.733 -74.36%
2019 1.062.501 39.41%
2020 538.498 -97.31%
2021 95.628 -463.12%
2022 398.089 75.98%
2023 79.996 -397.64%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Soligenix, Inc. Net Profit
Year Net Profit Growth
1995 -1.187.985
1997 -3.200.000 62.88%
1998 -21.800.000 85.32%
1999 -7.501.019 -190.63%
2000 -4.795.693 -56.41%
2001 -14.631.175 67.22%
2002 -4.966.081 -194.62%
2003 -5.288.531 6.1%
2004 -5.871.574 9.93%
2005 -4.720.260 -24.39%
2006 -8.163.346 42.18%
2007 -6.164.643 -32.42%
2008 -3.422.027 -80.15%
2009 -6.034.453 43.29%
2010 -7.386.579 18.31%
2011 -2.378.594 -210.54%
2012 -4.163.008 42.86%
2013 -10.058.996 58.61%
2014 -6.706.972 -49.98%
2015 -7.831.230 14.36%
2016 -3.245.383 -141.3%
2017 -7.147.083 54.59%
2018 -8.899.975 19.7%
2019 -9.355.592 4.87%
2020 -17.688.522 47.11%
2021 -12.550.973 -40.93%
2022 -13.798.339 9.04%
2023 -6.650.808 -107.47%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Soligenix, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 -703
1997 -3.056 77%
1998 -6.568 53.47%
1999 -2.092 -213.96%
2000 -1.180 -77.29%
2001 -3.264 63.84%
2002 -662 -392.9%
2003 -544 -21.92%
2004 -434 -25.4%
2005 -285 -52.46%
2006 -384 26.04%
2007 -204 -89.16%
2008 -101 -103%
2009 -108 7.41%
2010 -109 0.92%
2011 -33 -240.63%
2012 -56 42.86%
2013 -98 42.27%
2014 -49 -102.08%
2015 -45 -6.67%
2016 -14 -246.15%
2017 -17 23.53%
2018 -10 -70%
2019 -7 -42.86%
2020 -10 22.22%
2021 -4 -125%
2022 -4 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Soligenix, Inc. Free Cashflow
Year Free Cashflow Growth
1995 -1.070.286
1997 -2.400.000 55.4%
1998 -4.300.000 44.19%
1999 -2.084.648 -106.27%
2000 -3.535.882 41.04%
2001 -4.116.220 14.1%
2002 -6.083.889 32.34%
2003 -4.236.360 -43.61%
2004 -4.418.335 4.12%
2005 -4.942.833 10.61%
2006 -4.350.386 -13.62%
2007 -6.361.195 31.61%
2008 -3.030.762 -109.89%
2009 -4.825.718 37.2%
2010 -6.067.006 20.46%
2011 -2.104.402 -188.3%
2012 -2.640.288 20.3%
2013 -4.474.701 41%
2014 -2.517.595 -77.74%
2015 -5.408.406 53.45%
2016 -4.989.580 -8.39%
2017 -6.536.915 23.67%
2018 -7.246.556 9.79%
2019 -7.539.776 3.89%
2020 -11.461.573 34.22%
2021 -11.751.409 2.47%
2022 -12.662.094 7.19%
2023 -2.686.316 -371.36%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Soligenix, Inc. Operating Cashflow
Year Operating Cashflow Growth
1995 -1.002.330
1997 -2.300.000 56.42%
1998 -4.100.000 43.9%
1999 -1.976.775 -107.41%
2000 -3.449.697 42.7%
2001 -3.976.564 13.25%
2002 -6.000.800 33.73%
2003 -4.218.506 -42.25%
2004 -4.407.776 4.29%
2005 -4.670.702 5.63%
2006 -4.141.830 -12.77%
2007 -5.997.833 30.94%
2008 -2.788.372 -115.1%
2009 -4.603.189 39.43%
2010 -5.730.582 19.67%
2011 -1.951.738 -193.61%
2012 -2.635.533 25.95%
2013 -4.456.973 40.87%
2014 -2.466.729 -80.68%
2015 -5.386.308 54.2%
2016 -4.982.421 -8.11%
2017 -6.510.567 23.47%
2018 -7.244.631 10.13%
2019 -7.509.567 3.53%
2020 -11.454.426 34.44%
2021 -11.739.620 2.43%
2022 -12.649.021 7.19%
2023 -2.686.316 -370.87%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Soligenix, Inc. Capital Expenditure
Year Capital Expenditure Growth
1995 67.956
1997 100.000 32.04%
1998 200.000 50%
1999 107.873 -85.4%
2000 86.185 -25.16%
2001 139.656 38.29%
2002 83.089 -68.08%
2003 17.854 -365.38%
2004 10.559 -69.09%
2005 272.131 96.12%
2006 208.556 -30.48%
2007 363.362 42.6%
2008 242.390 -49.91%
2009 222.529 -8.93%
2010 336.424 33.85%
2011 152.664 -120.37%
2012 4.755 -3110.6%
2013 17.728 73.18%
2014 50.866 65.15%
2015 22.098 -130.18%
2016 7.159 -208.67%
2017 26.348 72.83%
2018 1.925 -1268.73%
2019 30.209 93.63%
2020 7.147 -322.68%
2021 11.789 39.38%
2022 13.073 9.82%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Soligenix, Inc. Equity
Year Equity Growth
1995 1.378.191
1997 18.400.000 92.51%
1998 6.300.000 -192.06%
1999 7.256.154 13.18%
2000 10.546.145 31.2%
2001 -2.628.949 501.15%
2002 4.285.633 161.34%
2003 5.244.774 18.29%
2004 2.983.583 -75.79%
2005 1.528.073 -95.25%
2006 -1.108.456 237.86%
2007 2.590.366 142.79%
2008 1.977.116 -31.02%
2009 8.174.226 75.81%
2010 7.357.791 -11.1%
2011 6.791.042 -8.35%
2012 3.551.106 -91.24%
2013 -1.769.821 300.65%
2014 -153.889 -1050.06%
2015 -18.309 -740.51%
2016 7.397.248 100.25%
2017 6.319.712 -17.05%
2018 6.280.170 -0.63%
2019 1.457.135 -330.99%
2020 3.741.828 61.06%
2021 10.722.598 65.1%
2022 -2.470.826 533.97%
2023 4.221.155 158.53%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Soligenix, Inc. Assets
Year Assets Growth
1995 1.435.674
1997 19.100.000 92.48%
1998 16.200.000 -17.9%
1999 9.272.125 -74.72%
2000 13.669.458 32.17%
2001 11.041.619 -23.8%
2002 5.838.200 -89.13%
2003 6.252.066 6.62%
2004 5.067.715 -23.37%
2005 3.372.574 -50.26%
2006 1.406.970 -139.7%
2007 3.783.879 62.82%
2008 3.362.735 -12.52%
2009 9.384.282 64.17%
2010 9.268.547 -1.25%
2011 8.223.658 -12.71%
2012 4.705.104 -74.78%
2013 8.265.455 43.08%
2014 6.954.248 -18.85%
2015 7.387.122 5.86%
2016 10.267.105 28.05%
2017 9.549.651 -7.51%
2018 10.491.702 8.98%
2019 7.775.360 -34.94%
2020 19.891.235 60.91%
2021 26.869.927 25.97%
2022 14.279.717 -88.17%
2023 11.302.829 -26.34%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Soligenix, Inc. Liabilities
Year Liabilities Growth
1995 57.483
1997 700.000 91.79%
1998 1.500.000 53.33%
1999 2.015.971 25.59%
2000 3.123.313 35.45%
2001 13.670.568 77.15%
2002 1.552.567 -780.51%
2003 1.007.292 -54.13%
2004 2.084.132 51.67%
2005 1.844.501 -12.99%
2006 2.515.426 26.67%
2007 1.193.513 -110.76%
2008 1.385.619 13.86%
2009 1.210.056 -14.51%
2010 1.910.756 36.67%
2011 1.432.616 -33.38%
2012 1.153.998 -24.14%
2013 10.035.276 88.5%
2014 7.108.137 -41.18%
2015 7.405.431 4.01%
2016 2.869.857 -158.04%
2017 3.229.939 11.15%
2018 4.211.532 23.31%
2019 6.318.225 33.34%
2020 16.149.407 60.88%
2021 16.147.329 -0.01%
2022 16.750.543 3.6%
2023 7.081.674 -136.53%

Soligenix, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.09
Net Income per Share
-0.89
Price to Earning Ratio
-0.96x
Price To Sales Ratio
9.19x
POCF Ratio
-0.85
PFCF Ratio
-0.85
Price to Book Ratio
2.09
EV to Sales
1.77
EV Over EBITDA
-0.19
EV to Operating CashFlow
-0.16
EV to FreeCashFlow
-0.16
Earnings Yield
-1.05
FreeCashFlow Yield
-1.18
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
2.85
Graham NetNet
0.32

Income Statement Metrics

Net Income per Share
-0.89
Income Quality
1.29
ROE
-8.87
Return On Assets
-0.63
Return On Capital Employed
-2.18
Net Income per EBT
0.78
EBT Per Ebit
1
Ebit per Revenue
-9.46
Effective Tax Rate
0.23

Margins

Sales, General, & Administrative to Revenue
4.73
Research & Developement to Revenue
5.09
Stock Based Compensation to Revenue
0.36
Gross Profit Margin
0.11
Operating Profit Margin
-9.46
Pretax Profit Margin
-9.43
Net Profit Margin
-7.32

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1
Free CashFlow per Share
-1
Capex to Operating CashFlow
-0
Capex to Revenue
0.01
Capex to Depreciation
1.64
Return on Invested Capital
-1.18
Return on Tangible Assets
-0.82
Days Sales Outstanding
33.78
Days Payables Outstanding
812.29
Days of Inventory on Hand
0
Receivables Turnover
10.81
Payables Turnover
0.45
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,99
Book Value per Share
0,41
Tangible Book Value per Share
0.41
Shareholders Equity per Share
0.41
Interest Debt per Share
0.33
Debt to Equity
0.75
Debt to Assets
0.28
Net Debt to EBITDA
0.78
Current Ratio
1.99
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.75
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.36

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Soligenix, Inc. Dividends
Year Dividends Growth

Soligenix, Inc. Profile

About Soligenix, Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

CEO
Dr. Christopher J. Schaber Ph.
Employee
13
Address
29 Emmons Drive
Princeton, 08540

Soligenix, Inc. Executives & BODs

Soligenix, Inc. Executives & BODs
# Name Age
1 Dr. Christopher J. Schaber Ph.D.
Chairman of the Board of Directors, Chief Executive Officer & President
70
2 Mr. Jonathan L. Guarino CPA, CGMA
Senior Vice President, Chief Financial Officer & Corporate Secretary
70
3 Dr. Oreola Donini Ph.D.
Senior Vice President & Chief Scientific Officer
70
4 Dr. Richard C. Straube M.D., MSc.
Senior Vice President & Chief Medical Officer
70

Soligenix, Inc. Competitors